The delayed onset and long duration of action of the opioid agonist levo‐α‐acetyl‐methadol
(LAAM) has been attributed to the formation of active metabolites. However, at present, little …

Levo-α-acetylmethadol (LAAM) is a long-acting opioid agonist approved for use as a
maintenance treatment for opioid dependence. Previous clinical studies report that the onset …

Methadone is currently the most widely used agent to manage opioid dependence, but
clinical experience has highlighted some limitations with its use. In particular, a relatively …

The purpose of this study was to examine the effects of acute and chronic treatment with l-α-
acetylmethadol (LAAM), a long-acting mu opioid agonist that is used to treat opioid …

levo-α-Acetylmethadol (LAAM) and methadone are full μ-opioid agonists used to treat opioid
dependence. Current labeling indicates that LAAM is less potent than methadone. Clinical …

Pharmacodynamic profiles of 1-alpha-acetylmethadol (LAAM) and its N-demethylated
metabolites, nor-LAAM and dinor-LAAM, during self-administration in the dependent rat.

The pharmacokinetics of the synthetic narcotic agent LAAM, its pharmacologically active,
demethylated metabolites NORLAAM and DINORLAAM, and also the dextro‐enantiomer …

Although l-α-acetylmethadol (LAAM) is a maintenance treatment for opioid dependence, few
studies have systematically assessed the behavioral effects of LAAM and other drugs in …

Levo-α-acetylmethadol (LAAM) currently is approved as an opioid maintenance treatment.
This double-blind study was designed to characterize withdrawal suppression and opioid …

A gas chromatography–mass spectrometry (GC–MS) method is presented which allows the
simultaneous determination of the plasma concentrations of the levo-α-acetylmethadol …